STRO
USDSutro Biopharma Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.240
Kõrge
$1.240
Madal
$0.832
Maht
0.06M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
108.9M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.76M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma from Buy to Neutral and lowers the price target from $12 to $2.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform
Citizens Capital Markets analyst Reni Benjamin downgrades Sutro Biopharma from Market Outperform to Market Perform.
Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
Wedbush analyst David Nierengarten downgrades Sutro Biopharma from Outperform to Neutral and lowers the price target from $8 to $2.
B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1
B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma from Buy to Underperform and lowers the price target from $11 to $1.
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.